Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.

McHugh DJ, Funt SA, Silber D, Knezevic A, Patil S, O'Donnell D, Tsai S, Reuter VE, Sheinfeld J, Carver BS, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR.

J Clin Oncol. 2020 Feb 28:JCO1902712. doi: 10.1200/JCO.19.02712. [Epub ahead of print]

PMID:
32109195
2.

Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors.

Caso R, Jones GD, Bains MS, Hsu M, Tan KS, Feldman DR, Funt SA, Reuter VE, Bosl GJ, McHugh D, Huang J, Molena D, Amar D, Fischer G, Rusch VW, Jones DR.

Ann Surg. 2020 Jan 21. doi: 10.1097/SLA.0000000000003754. [Epub ahead of print]

PMID:
31977510
3.

Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum.

Sheinfeld J, Feldman DR, DiNatale RG, Bosl GJ.

Eur Urol. 2019 Nov;76(5):612-614. doi: 10.1016/j.eururo.2019.07.016. Epub 2019 Jul 18. No abstract available.

PMID:
31327637
4.

Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

Funt SA, Patil S, Feldman DR, Motzer RJ, Bajorin DF, Sheinfeld J, Tickoo SK, Reuter VE, Bosl GJ.

J Clin Oncol. 2019 Sep 10;37(26):2329-2337. doi: 10.1200/JCO.18.01608. Epub 2019 Jun 24.

5.

Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.

Miller MI, Feifer A, Feldman DR, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J.

Urology. 2019 Feb;124:174-178. doi: 10.1016/j.urology.2018.09.024. Epub 2018 Oct 6.

6.

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.

Pietzak EJ, Assel M, Becerra MF, Tennenbaum D, Feldman DR, Bajorin DF, Motzer RJ, Bosl GJ, Carver BS, Sjoberg DD, Sheinfeld J.

Urology. 2018 Aug;118:114-118. doi: 10.1016/j.urology.2018.04.009. Epub 2018 Apr 25.

7.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

Dowling CM, Assel M, Musser JE, Meeks JJ, Sjoberg DD, Bosl G, Motzer R, Bajorin D, Feldman D, Carver BS, Sheinfeld J.

Urology. 2018 Apr;114:133-138. doi: 10.1016/j.urology.2018.01.014. Epub 2018 Feb 2.

8.

Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

van de Wetering RAW, Sleijfer S, Feldman DR, Funt SA, Bosl GJ, de Wit R.

J Clin Oncol. 2018 Mar 20;36(9):837-840. doi: 10.1200/JCO.2017.76.5610. Epub 2018 Feb 1. No abstract available.

9.

Development of a Geriatric Service in a Cancer Center: Lessons Learned.

Korc-Grodzicki B, Tew W, Hurria A, Yulico H, Lichtman S, Hamlin P, Bosl G.

J Oncol Pract. 2017 Feb;13(2):107-112. doi: 10.1200/JOP.2016.017590. No abstract available.

10.

How We Care for an Older Patient With Cancer.

Shahrokni A, Kim SJ, Bosl GJ, Korc-Grodzicki B.

J Oncol Pract. 2017 Feb;13(2):95-102. doi: 10.1200/JOP.2016.017608.

11.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

12.

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT, Hanna NH, Albany C, Foster R, Cedermark GC, Feldman DR, Powles T, Lewis MA, Grimison PS, Bank D, Porter C, Albers P, De Santis M, Srinivas S, Bosl GJ, Nichols CR.

J Clin Oncol. 2017 Nov 1;35(31):3525-3528. doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30. No abstract available.

13.

Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy.

Kopp RP, Chevinsky M, Bernstein M, Bosl G, Motzer R, Bajorin D, Feldman D, Carver BS, Sheinfeld J.

Urology. 2017 May;103:154-160. doi: 10.1016/j.urology.2016.10.018. Epub 2016 Nov 2.

14.

Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.

Mano R, Becerra MF, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Feldman DR, Sheinfeld J.

J Urol. 2017 Feb;197(2):391-397. doi: 10.1016/j.juro.2016.09.113. Epub 2016 Oct 5.

15.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR.

J Clin Oncol. 2016 Nov 20;34(33):4000-4007. doi: 10.1200/JCO.2016.68.7798. Epub 2016 Sep 30.

16.

The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach.

Funt SA, Feldman DR, Bosl GJ.

Oncology (Williston Park). 2016 Jul;30(7):653-64. Review.

17.

Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience.

Alanee SR, Carver BS, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2016 Sep;95:128-31. doi: 10.1016/j.urology.2016.05.014. Epub 2016 May 25.

18.

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ.

J Clin Oncol. 2016 Jul 20;34(21):2478-83. doi: 10.1200/JCO.2016.66.7899. Epub 2016 May 16.

19.

Recurrent Germ Cell Tumors: Let's Try to Cure Them All.

Bosl GJ.

J Oncol Pract. 2016 May;12(5):445-7. doi: 10.1200/JOP.2016.012187. No abstract available.

PMID:
27170694
20.

Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification.

Kushwaha R, Jagadish N, Kustagi M, Mendiratta G, Seandel M, Soni R, Korkola JE, Thodima V, Califano A, Bosl GJ, Chaganti RSK.

Stem Cell Reports. 2016 May 10;6(5):772-783. doi: 10.1016/j.stemcr.2016.04.002. Epub 2016 Apr 28.

21.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.

Korkola JE, Heck S, Olshen AB, Feldman DR, Reuter VE, Houldsworth J, Bosl GJ, Chaganti RS.

PLoS One. 2015 Dec 1;10(12):e0142846. doi: 10.1371/journal.pone.0142846. eCollection 2015.

22.

Development of a risk stratification system to guide treatment for female germ cell tumors.

Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S, Jacobsen EP, Murali R, Gardner GJ, Bosl GJ, Aghajanian C, Feldman DR.

Gynecol Oncol. 2015 Sep;138(3):566-72. doi: 10.1016/j.ygyno.2015.06.029. Epub 2015 Jun 24.

23.

Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

Feldman DR, Glezerman I, Patil S, Van Alstine L, Bajorin DF, Fischer P, Hughes A, Sheinfeld J, Bains M, Reich L, Woo K, Giralt S, Bosl GJ, Motzer RJ.

Clin Genitourin Cancer. 2015 Oct;13(5):453-60. doi: 10.1016/j.clgc.2015.05.003. Epub 2015 May 16.

24.

Germ cell tumors: looking to the future.

Bosl GJ.

Am Soc Clin Oncol Educ Book. 2015:e253-8. doi: 10.14694/EdBook_AM.2015.35.e253.

25.

Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?

Iasonos A, Gönen M, Bosl GJ.

J Clin Oncol. 2015 Jul 1;33(19):2221-5. doi: 10.1200/JCO.2014.59.8466. Epub 2015 May 4. No abstract available.

26.

Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency.

Kushwaha R, Jagadish N, Kustagi M, Tomishima MJ, Mendiratta G, Bansal M, Kim HR, Sumazin P, Alvarez MJ, Lefebvre C, Villagrasa-Gonzalez P, Viale A, Korkola JE, Houldsworth J, Feldman DR, Bosl GJ, Califano A, Chaganti RS.

Stem Cells. 2015 Feb;33(2):367-77. doi: 10.1002/stem.1870.

27.

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.

Kundu SD, Feldman DR, Carver BS, Gupta A, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J.

J Urol. 2015 Feb;193(2):513-8. doi: 10.1016/j.juro.2014.08.081. Epub 2014 Aug 20.

28.

Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.

Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie H, Reuter VE, Bosl GJ, Chaganti RS, Solit DB.

Clin Cancer Res. 2014 Jul 15;20(14):3712-20. doi: 10.1158/1078-0432.CCR-13-2868. Epub 2014 May 8.

29.

Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.

Silberstein JL, Bazzi WM, Vertosick E, Carver BS, Bosl GJ, Feldman DR, Bajorin DF, Motzer RJ, Al-Ahmadie H, Reuter VE, Sheinfeld J.

J Urol. 2014 Aug;192(2):415-9. doi: 10.1016/j.juro.2014.01.104. Epub 2014 Feb 8.

30.

miR-18b and miR-518b Target FOXN1 during epithelial lineage differentiation in pluripotent cells.

Kushwaha R, Thodima V, Tomishima MJ, Bosl GJ, Chaganti RS.

Stem Cells Dev. 2014 May 15;23(10):1149-56. doi: 10.1089/scd.2013.0262. Epub 2014 Mar 21.

PMID:
24383669
31.

Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.

Al-Ahmadie HA, Carver BS, Cronin AM, Olgac S, Tickoo SK, Fine SW, Gopalan A, Stasi J, Rabbani F, Bosl GJ, Sheinfeld J, Reuter VE.

Urology. 2013 Dec;82(6):1341-6. doi: 10.1016/j.urology.2013.04.082. Epub 2013 Oct 2.

PMID:
24094656
32.

Reply: To PMID 24094653.

Al-Ahmadie H, Sheinfeld J, Bosl GJ, Reuter VE.

Urology. 2013 Dec;82(6):1346-7. doi: 10.1016/j.urology.2013.04.084. Epub 2013 Oct 2. No abstract available.

PMID:
24094654
33.

Optimal management of clinical stage I testis cancer: one size does not fit all.

de Wit R, Bosl GJ.

J Clin Oncol. 2013 Oct 1;31(28):3477-9. doi: 10.1200/JCO.2013.51.0479. Epub 2013 Sep 3. No abstract available.

PMID:
24002512
34.

Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.

Feldman DR, Voss MH, Jacobsen EP, Jia X, Suarez JA, Turkula S, Sheinfeld J, Bosl GJ, Motzer RJ, Patil S.

Cancer. 2013 Jul 15;119(14):2574-81. doi: 10.1002/cncr.28025. Epub 2013 Apr 19.

35.

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.

Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M.

PLoS One. 2012;7(12):e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12.

36.

Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.

Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD.

J Clin Oncol. 2012 Oct 20;30(30):3752-63. doi: 10.1200/JCO.2012.43.4431. Epub 2012 Sep 24.

PMID:
23008318
37.

Rare de novo germline copy-number variation in testicular cancer.

Stadler ZK, Esposito D, Shah S, Vijai J, Yamrom B, Levy D, Lee YH, Kendall J, Leotta A, Ronemus M, Hansen N, Sarrel K, Rau-Murthy R, Schrader K, Kauff N, Klein RJ, Lipkin SM, Murali R, Robson M, Sheinfeld J, Feldman D, Bosl G, Norton L, Wigler M, Offit K.

Am J Hum Genet. 2012 Aug 10;91(2):379-83. doi: 10.1016/j.ajhg.2012.06.019. Epub 2012 Aug 2.

38.

Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.

Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2012 May;79(5):1079-84. doi: 10.1016/j.urology.2011.11.090. Epub 2012 Mar 23.

PMID:
22446341
39.

Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.

Masterson TA, Carver BS, Abel EJ, Pettus JA, Bosl GJ, Sheinfeld J.

BJU Int. 2012 Oct;110(7):950-5. doi: 10.1111/j.1464-410X.2012.10947.x. Epub 2012 Mar 6.

40.

Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.

Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2012 Jan;79(1):156-9. doi: 10.1016/j.urology.2011.09.038.

PMID:
22202548
41.

Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman D, Reuter VE, Sheinfeld J.

Urology. 2012 Feb;79(2):361-4. doi: 10.1016/j.urology.2011.04.050. Epub 2011 Dec 14.

42.

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.

Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ.

Cancer. 2012 Feb 15;118(4):981-6. doi: 10.1002/cncr.26375. Epub 2011 Jul 26.

43.

Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center.

Sarkaria IS, Bains MS, Sood S, Sima CS, Reuter VE, Flores RM, Motzer RJ, Bosl GJ, Rusch VW.

J Thorac Oncol. 2011 Jul;6(7):1236-41. doi: 10.1097/JTO.0b013e31821d513e.

44.

A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.

Voss MH, Feldman DR, Bosl GJ, Motzer RJ.

Hematol Oncol Clin North Am. 2011 Jun;25(3):557-76, viii -ix. doi: 10.1016/j.hoc.2011.03.007. Epub 2011 Apr 22. Review.

45.

Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy.

Grommes C, Bosl GJ, DeAngelis LM.

Cancer. 2011 May 1;117(9):1911-6. doi: 10.1002/cncr.25693. Epub 2010 Nov 29.

46.

Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.

Gupta A, Feifer AH, Gotto GT, Kraus D, Motzer R, Bosl GJ, Bajorin D, Feldman DR, Carver B, Sheinfeld J.

Urology. 2011 Mar;77(3):655-9. doi: 10.1016/j.urology.2010.10.002.

PMID:
21377010
47.

Carboplatin in clinical stage I seminoma: too much and too little at the same time.

Bosl GJ, Patil S.

J Clin Oncol. 2011 Mar 10;29(8):949-52. doi: 10.1200/JCO.2010.29.5055. Epub 2011 Jan 31. No abstract available.

PMID:
21282532
48.

CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity.

Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H.

Radiology. 2011 Jan;258(1):41-56. doi: 10.1148/radiol.10092129. Review.

PMID:
21183492
49.

Contemporary lymph node counts during primary retroperitoneal lymph node dissection.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman DR, Reuter VE, Sheinfeld J.

Urology. 2011 Feb;77(2):368-72. doi: 10.1016/j.urology.2010.05.020. Epub 2010 Dec 15.

50.

Evaluation of lymph node counts in primary retroperitoneal lymph node dissection.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman D, Reuter VE, Sheinfeld J.

Cancer. 2010 Nov 15;116(22):5243-50. doi: 10.1002/cncr.25266.

Supplemental Content

Support Center